A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Merck Sharp & Dohme LLC
OncoC4, Inc.
Merck Sharp & Dohme LLC
Imugene Limited
AstraZeneca
DualityBio Inc.
Genfit
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Elicio Therapeutics
Leap Therapeutics, Inc.
Shanghai Bao Pharmaceuticals Co., Ltd.
Lisata Therapeutics, Inc.
Pfizer
Tempus AI